Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited showcased their DEP® HER2 radiotheranostics program at the prestigious SNMMI Annual Meeting, revealing that their dendrimer-based technology demonstrates enhanced tumor targeting and reduced organ exposure compared to the monoclonal antibody Herceptin®. These promising results suggest DEP® dendrimers could significantly improve precision radiotheranostics for cancer treatment. The company’s continued advancements in this field exemplify their commitment to developing innovative therapeutics utilizing dendrimer technology.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
